CJC-1295 vs Sermorelin
Updated: April 25, 2026
| Feature | CJC-1295 | Sermorelin |
|---|---|---|
| Family | GHRH | GHRH |
| Reconstituted handling | Cold-chain dependent | Cold-chain dependent |
| Freeze guidance | Avoid freezing | Avoid freezing |
| Confidence class | Medium | Medium |
Decision Framework
Use protocol objective, frequency tolerance, and monitoring discipline as primary decision criteria. Keep concentration and storage controls stable throughout the protocol window.
Stability Planning
Both compounds benefit from strict refrigeration and short handling windows per use. Tracking dates and potency estimates reduces interpretation drift.
Evidence Basis
- Freeze guidance — do not freeze reconstituted: Based on general GHRH peptide fragility and protein aggregation research. Mazur et al. — Freeze-thaw characterization of protein therapeutics (PMID 34059716, Sci Rep 2021); Hauptmann et al. — Freezing-induced aggregation (PMID 32335158, Int J Pharm 2020). Note: GHRH-specific freeze assay data is not available in peer-reviewed literature; classification is a conservative model estimate.
- CJC-1295 mechanism and pharmacology: Teichman et al. — prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults (PMID 16352683); Ionescu and Frohman — GH pulsatility during continuous CJC-1295 stimulation (PMID 17018654); Jette et al. — identification of CJC-1295 as a long-lasting GRF analog (PMID 15817669).
- Storage framework: ICH Q1A(R2) + ICH Q5C. Decay rates are [Model Estimates — PeptideClock].